Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- COMPLETED
- Phase
- PHASE2
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
- Status
- COMPLETED
- Phase
- PHASE1
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1